Newton Inc. announced that its Neurolens N3 measurement system has received CE marking under the European Union Medical Device Regulation (EU MDR), which clears the device for commercialization across the European Union and European Economic Area, in addition to the company's existing markets in the United States and Canada.
The N3 system uses eye-tracking technology to objectively measure ocular alignment at distance and near. Eyecare professionals can use this data to prescribe Neurolens with Contoured Prism technology to address symptoms associated with ocular misalignment, including headaches, neck and shoulder pain, and motion sickness. The headset-based measurement system provides a controlled testing environment and integrates into existing pretesting workflows. The automated assessment takes a few minutes and can be performed by trained staff, the company said.
The company also reported that clinical trial patients experienced an average 5-point reduction in Headache Impact Test-6 (HIT-6) scores after four weeks of Neurolens wear, and 90% of Neurolens wearers surveyed after 60 days experienced symptom improvement.
According to Newton, more than 4 million eye alignment measurements have been performed using Neurolens technology, and more than 350,000 patients have received Neurolens in North America.
Newton expects to introduce Neurolens in its first European markets in 2027. Additional countries are expected to follow.
Additional information is available at newton.tech.


